
The retrospective study of 353 HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy revealed that ER status, PR status, HER2 status, Ki-67 index, and chemotherapy regimens independently influenced pathological complete response (pCR) rates. A nomogram predicting pCR probability demonstrated an area under the curve of 0.73. Notably, ER-negative, PR-negative, HER2 3+, and high Ki-67 index patients were more likely to achieve pCR. The study suggests considering THP as an alternative to AC-THP or TCbHP in specific HER2-positive patients.
Like
Save
Share